Prescribing information

 

This page/content is for Great Britain Healthcare professionals only. If you require information for Northern Ireland please refer to the Northern Ireland PI

 

 

Below are a selection of resources to help you and your patients stay on track with PIQRAY® + fulvestrant.

 

Piqray Resources for Healthcare Professionals

 

Thumbnail of PIQRAY Management Guide document

THERAPY MANAGEMENT GUIDE

A brochure to provide guidance on the management of specific adverse events that your patients on PIQRAY® + fulvestrant may experience, and how to deliver the treatment with appropriate medical management.

Download a digital copy

Screenshot from the video: Dr Paul Nathan discusses the COMBI-AD trial

JOURNAL REPRINTS

For relevant journal publications, including a SOLAR-1 study reprint, please contact Novartis.

Download a digital copy

 

MOA VIDEO

A video depicting the mechanism of action for PIQRAY® against the PIK3CA mutation in HR+/HER2– advanced breast cancer.

 

 

Piqray Resources for Patients

 

Preview of 'Your guide to managing pyrexia'

PATIENT MANAGEMENT GUIDE

A booklet for you to share with your patients, to help them understand more about the treatment they have been prescribed.

Download a digital copy  Request a hard copy  

""

PATIENT SUPPORT WEBSITE

A website for patients in Great Britain who have been prescribed this medicine, to allow them to find out more about their treatment with PIQRAY® plus fulvestrant, such as how it works and the side effects they might experience. Please visit www.illuminatingabc.co.uk and use the password: connect@illuminatingABC

Access the patient website (GB HCPs to share with GB patients only)

 

As the site grows, we will be adding lots of new content. SIGN UP to receive our email communications and make sure you don’t miss the latest updates.

Rate this content: 
Average: 4 (1 vote)
UK | October 2023 | 307248

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]